Company Profile

Aviv Biomedical Inc
Profile last edited on: 11/20/19      CAGE: 0TDU9      UEI:

Business Identifier: Spectrometers and fluorometers
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

750 Vassar Avenue Suite 2
Lakewood, NJ 08701
   (732) 370-1300
Location: Single
Congr. District: 04
County: Ocean

Public Profile

Founded in 1971 by the late Jack Aviv, Aviv Biomedical initially serviced spectrophotometers, circular dichroism spectrometers and spectrofluorometers. A medical instrumentation developer, in 1975 -under license from Bell Telephone Research,- the company introduced a front surface fluorescence instrument to detect iron deficiency and lead poisoning in the blood, known as a Hematofluorometer. Specializing in circular dichroism (CD) spectroscopy, fluorescence detection for analytical ultracentrifugation, UV-Vis-IR spectroscopy, and fluorescence spectroscopy a number of innovative technologies were introduced to include CD spectroscopy - the first to have computer user interface, thermoelectric temperature control, simultaneous fluorescence measurements, fluorescence detected circular dichroism, super conducting magnetic CD, multiple automated titration experiments, and macro language. In 2018, the firm announced launch of a new initiative to identify one or more global partners for commercialisation of its newest product, the Bilirubin Hematofluorometer System (AVIV-BHS), for assessment of jaundice in newborn babies. For the first time, this new approach enables the the rapid measurement in neonates of Bilirubin Binding Capacity (BBC), a critical factor in preventing or allowing the development of neonatal jaundice. Bilirubin is neurotoxic, and high levels following birth can result in grave illnesses including seizures,cerebral palsy and kernicterus. Neonatal jaundice, caused by hyperbilirubinemia, is a common disorder in ~60% of newborns with ~18% of these at risk for neurological disorders or death. All modern hospitals monitor neonatal bilirubin levels (Total Serum Bilirubin or TSB), however, predicting risk solely on TSB levels is known to be inadequate.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 2 NIH $2,977,296
Project Title: Point-Of Care System for Determination of Bilirubin Capacity in Neonates
2005 1 NIH $99,973
Project Title: Advanced Absorbance Detection for the AUC

Key People / Management

  Glen D Ramsay -- Chief Scientist

Company News

There are no news available.